We examined adherence, medication-taking practices, and preferences to inform development of a wrist-worn adherence system. Two convenience samples of persons taking antiretroviral therapy and HIV pre-exposure prophylaxis completed a survey. Additional online questions asked about willingness to use a wrist-worn device and reminder and feedback preferences. Among 225 participants, 13% reported adherence < 90%; this was associated with younger age and clinic sample. Compared to pill bottle–us-ing participants, mediset users less commonly reported adherence < 90% (aOR = 0.16, p =.02), and blister pack users (aOR = 6.3, p =.02) and pill roll users (aOR = 3.3, p =.04) more commonly reported adherence < 90%. Sixty-two percent of the online participants reporting adherence (< 100%) had some interest in receiving adherence reminders, including 42% with interest in receiving reminders by smartwatch notifications. Although confounders are likely, formative work identified potential users and interest in using a wrist-worn adherence system. Future work will determine its acceptability and efficacy.
|Original language||English (US)|
|Number of pages||12|
|Journal||AIDS Education and Prevention|
|State||Published - Oct 2018|
Bibliographical noteFunding Information:
Joanne D. Stekler , Jane M. Simoni, Heidi M. Crane, and Rob J. Fredericksen are affiliated with the University of Washington, Seattle, Washington. James M. Scanlan and Barry G. Saver are affiliated with the Swedish Center for Research and Innovation, Seattle. Jenna Marquard is affiliated with the University of Massachusetts; Amherst, Massachusetts. Barry G. Saver is affiliated with the Swedish Medical Center, Seattle. We would like to thank the individuals who participated in this research for contributing their time. Support was provided by NIH R01 MH109319, the UW/Fred Hutch CFAR Clinical Research and Retrovi-rology Core (NIH P30 AI027757), the CFAR Network of Clinical Systems (CNICS, NIH R24AI067039), and the Institute of Translational Health Science (ITHS, NIH UL1TR000423). These data were presented in part at Adherence 2017, Miami, Florida, June 4–6, 2017: abstracts #217 and #357. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Address correspondence to Dr. Joanne Stekler, Box 359931, Harborview Medical Center, 325 Ninth Ave., Seattle, WA 98104. E-mail: email@example.com`
© 2018 The Guilford Press.
- Antiretroviral therapy
- Pre-exposure prophylaxis